With reference to the new share issue announced on March 22, 2022, Nanoform Finland Plc (“Nanoform” or the “Company“) is pleased to announce the result of the offering of new shares (the “Shares“) in an accelerated book building to Nordic and international institutional and other qualified investors (the “Placing“).

Nanoform expects to receive gross proceeds of approximately EUR 25 million as a result of the Placing. The Placing attracted a considerable number of global and Nordic institutional investors. The proceeds from the Placing will be used to accelerate Nanoform’s growth strategy with an investment in a new manufacturing site in the United States. The new manufacturing site in the USA, the world’s largest pharmaceutical market, is a natural next step for Nanoform, which increases proximity to existing and new customers.

In the Placing, the Company will issue a total of 5,581,818 Shares in a directed share issue. The Shares represent approximately 7.7 per cent of the issued shares in Nanoform prior to the Placing and approximately 7.1 per cent of the issued shares in Nanoform following the Placing. The total number of issued shares in the Company after the Placing will be 78,116,964.

The subscription price of the Shares is EUR 4.4 per Share (SEK 45.68 per Share), corresponding to a discount of approximately 8.3 per cent to the closing price on March 22, 2022 immediately before the commencement of the Placing. The subscription price shall be recorded in the invested unrestricted equity reserve.

The Placing was carried out based on offers received in an accelerated book building and based on the authorisations given to the board of directors by the Company’s annual general meeting of April 6, 2021.

Subject to the completion of the Placing, the Shares (ISIN code FI4000330972) will be registered with the trade register maintained by the Finnish Patent and Registration Office on or about March 23, 2022. The Shares are expected to be ready for delivery to the investors against payment through Euroclear Finland Ltd or, as applicable, through Euroclear Sweden AB on or about March 25, 2022. Trading in the Shares is expected to commence on Nasdaq First North Premier Growth Market Finland and Nasdaq First North Premier Growth Market Sweden on or about March 25, 2022.

The Company continues to be committed to the strong execution of its communicated strategy. The Company reached all its near-term targets for 2021 and is on track to deliver both on its near-term business targets for 2022 and its in June 2021 raised mid-term business targets for 2025. The funding from the Company’s IPO in 2020 and the directed share issue in March 2021 is still deemed sufficient for the growth strategy then communicated.

The CEO of Nanoform, Prof. Edward Hæggström comments: “We are pleased to see strong demand from new and existing global and Nordic institutional investors. With the raised funds we will accelerate Nanoform’s growth strategy with an investment in the US GMP manufacturing, a milestone we have prepared diligently.”

Danske Bank and SEB act as Joint Bookrunners and Joint Financial Advisors of the Placing. Borenius Attorneys Ltd is the legal counsel to the Company and to the Joint Bookrunners and Joint Financial Advisors as to Finnish law.